Immunocore Holdings Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Immunocore Holdings plc (IMCR) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-51.09-55.29-52.54-180.03-74.09
Depreciation & Amortization4.204.095.347.598.98
Deferred Income Tax0.000.00-3.53-12.69-13.27
Stock Based Compensation34.1932.4732.8948.8911.14
Change in Working Capital45.135.78-24.17-21.96-28.84
Change in Accounts Receivable-12.35-17.87-26.26-4.86-0.73
Change in Accounts Payable7.272.634.911.47-5.15
Change in Other Working Capital3.7529.0422.692.30-0.06
Other Operating Activities3.7515.89-10.722.30-1.70
Net Cash from Operating Activities26.062.94-49.21-143.11-61.25
Investing Activities
Capital Expenditures-5.17-5.43-2.20-1.39-2.02
Purchases of Investments-350.000.000.000.000.00
Sales/Maturities of Investments0.000.000.000.550.00
Other Investing Activities0.040.002.390.023.16
Net Cash from Investing Activities-355.13-5.43-2.20-1.281.14
Financing Activities
Debt Repayment-50.000.00-50.00-3.16-4.43
Common Stock Issued6.8034.35149.21286.8983.22
Other Financing Activities-15.420.00-1.77-20.98-0.18
Net Cash from Financing Activities343.8834.35145.44288.19115.94
Summary
Effect of Forex Changes on Cash-1.718.29-12.650.63-0.08
Net Change in Cash14.8140.1581.39143.8055.83
Cash at Beginning of Period442.63402.47321.08176.6673.97
Cash at End of Period455.73442.63402.47321.08129.72
Free Cash Flow20.89-2.49-51.41-144.49-64.32
Supplemental Disclosures
Interest Paid0.005.670.000.000.40
Income Taxes Paid0.510.980.77-17.04-55.02